Proton pump inhibitor use linked to low magnesium in dialysis patients
Proton pump inhibitors are more likely to cause low serum magnesium levels in hemodialysis patients, according to a new study reported in Hemodialysis International. Low magnesium levels in the presence of inflammation can in turn lead to an increased 1-year mortality rate, researchers found.
The study consisted of 399 hemodialysis patients. Of those patients, 243 were taking proton pump inhibitors at the time. Those patients exhibited significantly lower levels of magnesium than patients not taking a PPI. The lower levels could possibly have attributed to malnourishment and inflammation. 29 deaths occurred in the study, with patients who were taking a PPI dying at three times the rate as patients who were not taking a PPI.
PPIs are common drugs used to treat conditions such as heartburn, acid reflux and gastroesophageal reflux disease (GERD). Brand name PPIs include Prevacid, Prilosec and Nexium. PPIs have been linked to an increased risk of kidney disease and other kidney injuries. Patients have begun filing PPI lawsuits alleging that PPI manufacturers failed to warn doctors and patients about the increased risks of kidney disease associated with PPIs.